[Skip to Navigation]
Sign In
May 14, 1997

Adverse Outcomes of Underuse of β-Blockers in Elderly Patients

Author Affiliations

GD Searle & Co Skokie, Ill

JAMA. 1997;277(18):1434. doi:10.1001/jama.1997.03540420030016

To the Editor.  —The findings of Soumerai et al1 lump all calcium channel blockers into one group. While no calcium channel blocker is currently approved by the Food and Drug Administration for prevention of morbidity and mortality post-MI, data from several studies have shown that verapamil can reduce morbidity and mortality in some post-MI patients.The Second Danish Verapamil Infarction Trial (DAVIT II)2,3 randomized patients (<76 years of age) 7 to 15 days after hospital admission for AMI to receive either 120 mg of immediate-release verapamil 3 times per day (n=878) or placebo 3 times per day (n=897) for 12 to 18 months. Among the verapamil-treated patients, 289 were 65 years of age or older. In the intent-to-treat analyses for the total study population, verapamil was associated with a nonsignificant reduction in the 18-month mortality rate (20%) and a significant reduction in the major event (20%) rate vs placebo. Subgroup analysis

Add or change institution